175 related articles for article (PubMed ID: 38745123)
61. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
62. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
[TBL] [Abstract][Full Text] [Related]
63. Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome.
Sasayama D; Hattori K; Ogawa S; Yokota Y; Matsumura R; Teraishi T; Hori H; Ota M; Yoshida S; Kunugi H
Hum Mol Genet; 2017 Jan; 26(1):44-51. PubMed ID: 28031287
[TBL] [Abstract][Full Text] [Related]
64. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Loupakis F; Cremolini C; Fioravanti A; Orlandi P; Salvatore L; Masi G; Di Desidero T; Canu B; Schirripa M; Frumento P; Di Paolo A; Danesi R; Falcone A; Bocci G
Br J Cancer; 2011 Apr; 104(8):1262-9. PubMed ID: 21407216
[TBL] [Abstract][Full Text] [Related]
65. High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect to Aging and Genetic Factors.
Di Narzo AF; Telesco SE; Brodmerkel C; Argmann C; Peters LA; Li K; Kidd B; Dudley J; Cho J; Schadt EE; Kasarskis A; Dobrin R; Hao K
PLoS Genet; 2017 Jan; 13(1):e1006565. PubMed ID: 28129359
[TBL] [Abstract][Full Text] [Related]
66. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
67. Genome-wide pQTL analysis of protein expression regulatory networks in the human liver.
He B; Shi J; Wang X; Jiang H; Zhu HJ
BMC Biol; 2020 Aug; 18(1):97. PubMed ID: 32778093
[TBL] [Abstract][Full Text] [Related]
68. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
[TBL] [Abstract][Full Text] [Related]
69.
Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
[TBL] [Abstract][Full Text] [Related]
70. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
71. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
[TBL] [Abstract][Full Text] [Related]
72. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Ulivi P; Canale M; Passardi A; Marisi G; Valgiusti M; Frassineti GL; Calistri D; Amadori D; Scarpi E
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361687
[TBL] [Abstract][Full Text] [Related]
73. A functional polymorphism in lnc-LAMC2-1:1 confers risk of colorectal cancer by affecting miRNA binding.
Gong J; Tian J; Lou J; Ke J; Li L; Li J; Yang Y; Gong Y; Zhu Y; Zhang Y; Zhong R; Chang J; Miao X
Carcinogenesis; 2016 May; 37(5):443-51. PubMed ID: 26905585
[TBL] [Abstract][Full Text] [Related]
74. An Integrative Genomic Strategy Identifies sRAGE as a Causal and Protective Biomarker of Lung Function.
Keefe J; Yao C; Hwang SJ; Courchesne P; Lee GY; Dupuis J; Mizgerd JP; O'Connor G; Washko GR; Cho MH; Silverman EK; Levy D
Chest; 2022 Jan; 161(1):76-84. PubMed ID: 34237330
[TBL] [Abstract][Full Text] [Related]
75. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Tabernero J; Hozak RR; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Prausová J; Muro K; Siegel RW; Konrad RJ; Ouyang H; Melemed SA; Ferry D; Nasroulah F; Van Cutsem E
Ann Oncol; 2018 Mar; 29(3):602-609. PubMed ID: 29228087
[TBL] [Abstract][Full Text] [Related]
76. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
[TBL] [Abstract][Full Text] [Related]
77. LncRNA XIST enhanced TGF-β2 expression by targeting miR-141-3p to promote pancreatic cancer cells invasion.
Sun J; Zhang Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31213574
[TBL] [Abstract][Full Text] [Related]
78. Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab.
Hansen TF; Andersen RF; Olsen DA; Sørensen FB; Jakobsen A
Sci Rep; 2017 May; 7(1):2388. PubMed ID: 28539619
[TBL] [Abstract][Full Text] [Related]
79. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D
Yuan C; Renfro L; Ambadwar PB; Ou FS; McLeod HL; Innocenti F; Meyerhardt JA; Wolpin BM; Goldberg RM; Grothey A; Fuchs CS; Ng K
Cancer Causes Control; 2019 Jul; 30(7):757-765. PubMed ID: 31104167
[TBL] [Abstract][Full Text] [Related]
80. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
